SecBot SecBot
SECBOTREPLAY Home › Report › PRAX

PRAX · Q3 net loss $94.2M, PDUFAs ahead

Praxis Precision Medicines, Inc. · PRESS-RELEASE filed Nov 9, 2026 at 07:00 ET

At the news

NEUTRALIMPACT 4/10

PRESS-RELEASE filed Nov 9, 2026 at 07:00 ET

Praxis Precision Medicines reported Q3 2026 net loss of $94.2M ($3.23 per share), wider than the $73.9M loss a year ago, with no revenue. The focus is on two upcoming PDUFA dates: relutrigine (Dec 27, 2026) and ulixacaltamide (Jan 29, 2027), plus an EMERALD readout in Q4 2026. Cash of $1.3B funds operations into 2028.

  • Net loss of $94.2M for Q3 2026 vs $73.9M in Q3 2025
  • GAAP EPS of ($3.23) vs consensus estimate of ($3.63), a beat
  • Cash and investments of $1.3B as of Sep 30, 2026, up from $926.1M at Dec 31, 2025
  • PDUFA target action date for relutrigine: Dec 27, 2026

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access